Micro Robot-B (02252) issued a profit warning, expecting the adjusted net loss in the first half of the year not to exceed 125 million yuan, a year-on-year decrease of over 40%.

Wisdom Financial News APP informed that MicroPort Robotics-B (02252) announced that the company expects its revenue to increase by approximately 70% to 80% year-on-year in the first half of 2025, mainly due to the following reasons: the core product Tumai endoscopic surgical robot continued to maintain strong growth momentum during the period, especially in the overseas market with 18 new orders signed in the first half of the year, achieving commercial installations of over 13 units, becoming the core engine of revenue growth. The Honghu Orthopedic Surgical Robot fully utilized the mature sales network of MicroPort Medical Group in domestic and foreign markets, achieving rapid coverage and penetration of core regions, while independently developing new emerging regions, creating a "dual-drive" model for steady growth. After the approval and listing of the R-ONE vascular interventional surgical robot, it has gained market recognition and seen a steady increase in demand.